News

Making progress and achieving milestones to create innovative medicines

See our latest press releases about our news and progress.

Latest News

Filter by:

October 31, 2024

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

July 16, 2024

Ventus Therapeutics Significantly Expands its Presence in Montreal, Canada with Opening of a New Laboratory and Office Facility

May 3, 2024

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

April 17, 2024

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor

April 8, 2024

Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

January 3, 2024

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

January 2, 2024

Ventus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

November 9, 2023

Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference

September 6, 2023

Ventus Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 28, 2023

Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023

August 22, 2023

Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor

June 1, 2023

Ventus Therapeutics to Present at the Canadian Chemistry Conference and Exhibition

May 1, 2023

Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor

April 20, 2023

Ventus Therapeutics Awarded Grant by The Michael J. Fox Foundation to Support Development of a NLRP3 PET Tracer

April 17, 2023

Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity

April 13, 2023

Ventus Therapeutics to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference

January 5, 2023

Ventus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise

December 1, 2022

Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit

October 6, 2022

Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE™ Platform at Next Generation Undruggable Conference

September 29, 2022

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

September 6, 2022

Ventus Therapeutics Opens New Facility in Waltham, MA as First Phase of Global Expansion

July 7, 2022

Ventus Therapeutics Promotes Daniel Koerwer to Chief Operating Officer

May 9, 2022

Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus

May 2, 2022

Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer

April 4, 2022

Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences

March 31, 2022

Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer

February 9, 2022

Ventus Therapeutics Closes $140 Million Series C Financing

January 6, 2022

Ventus Therapeutics Announces Publication in Journal of Experimental Medicine Describing Advances in Structure-based Drug Discovery for Inflammasome Targets

December 17, 2021

Ventus Therapeutics Appoints John Chodera, Ph.D. and Tom Kurtzman, Ph.D. to its Scientific Advisory Board

December 7, 2021

Ventus Therapeutics Appoints Three New Members to Board of Directors

November 18, 2021

Ventus Therapeutics to Present Data for Novel Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases

November 3, 2021

Ventus Therapeutics to Present Data on Novel cGAS Small Molecule Inhibitors in the Modulation of Auto-Inflammation

September 24, 2021

Ventus Therapeutics to Present Data for Novel Peripherally Restricted and Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases

September 7, 2021

Ventus Therapeutics Appoints Christopher Bayly, PhD to its Scientific Advisory Board

July 20, 2021

Ventus Therapeutics Strengthens Computational Team and Capabilities

April 8, 2021

Ventus Therapeutics Closes $100 Million Series B Financing

January 25, 2021

Ventus Announces Promotion of Michael Crackower, PhD, to Chief Scientific Officer

November 16, 2020

Ventus Therapeutics Named to C&E News 10 Start-Ups to Watch 2020 List

September 15, 2020

Ventus Therapeutics Appoints Industry Veteran, Steven James, to Board of Directors

May 6, 2020

Ventus Therapeutics Launches with $60 Million Series A